Please assess the completion status of the following clinical trial:

Trial Title: Study to Compare the Bioavailability, Safety and Tolerability of XM17 in Healthy, Down Regulated Young Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Having signed written informed consent~* Healthy female subjects of any racial origin~* 18-39 years at the time of screening~* Body mass index (BMI) between 18-29 kg/m2 and a body weight of ≥ 50 kg~* Use of oral contraceptives for contraceptive purposes only and not for regularization of menstrual cycle, for at least 3 months~* Normal uterus and two functioning ovaries~* Agrees to use an adequate method of contraception during the study~* Non-smoking or moderate smokers of \< 10 cigarettes a day~Exclusion Criteria:~* Pregnancy~* Polycystic ovary syndrome, impaired ovarian function, severe endometriosis class III or IV, submucosal myoma uteri~* History of endocrine abnormalities with treatment within the last six months.~* Contraindications for the use of gonadotropins and goserelin~* Breast-feeding or being within a period of 2 months after delivery or abortion.~* Use of an injectable hormonal contraceptive within a period of 6 months prior to screening~* Treatment in the previous three months with any drug known to have a well-defined potential for toxicity to a major organ

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 39 Years
- Healthy Volunteers: t

Study Arms:
- XM17 (Type: EXPERIMENTAL): XM17 will be administered by 1 mL syringes in graduated steps of 0.01 mL.
- Gonal-f® (Type: EXPERIMENTAL): Gonal-f® will be provided in pens with integrated vials of 0.5 mL
- Zoladex® (Type: ACTIVE_COMPARATOR): Zoladex® 3.6 mg will be administered by subcutaneous injection

Based on this trial design, predict the completion outcome and termination type (if applicable).